IT202000004069A1 - Composizioni topiche per il mantenimento e/o ripristino dell’integrità delle mucose e dell’epidermide lesa - Google Patents
Composizioni topiche per il mantenimento e/o ripristino dell’integrità delle mucose e dell’epidermide lesa Download PDFInfo
- Publication number
- IT202000004069A1 IT202000004069A1 IT102020000004069A IT202000004069A IT202000004069A1 IT 202000004069 A1 IT202000004069 A1 IT 202000004069A1 IT 102020000004069 A IT102020000004069 A IT 102020000004069A IT 202000004069 A IT202000004069 A IT 202000004069A IT 202000004069 A1 IT202000004069 A1 IT 202000004069A1
- Authority
- IT
- Italy
- Prior art keywords
- compositions
- compositions according
- mucous membranes
- hyaluronic acid
- mucosa
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 47
- 230000000699 topical effect Effects 0.000 title claims description 9
- 210000004877 mucosa Anatomy 0.000 title description 11
- 238000012423 maintenance Methods 0.000 title description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 13
- 229920002674 hyaluronan Polymers 0.000 claims description 13
- 229960003160 hyaluronic acid Drugs 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 239000000499 gel Substances 0.000 claims description 11
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 9
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 9
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 8
- 230000003232 mucoadhesive effect Effects 0.000 claims description 7
- 239000008777 Glycerylphosphorylcholine Substances 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 4
- 229920002498 Beta-glucan Polymers 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- HTLWOXWXUHOLEJ-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;icos-1-ene Chemical compound C=CN1CCCC1=O.CCCCCCCCCCCCCCCCCCC=C HTLWOXWXUHOLEJ-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 2
- -1 ascorbic acid ester Chemical class 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 2
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims description 2
- 229950005134 polycarbophil Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
- 230000009471 action Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000009472 formulation Methods 0.000 description 7
- 229960002773 hyaluronidase Drugs 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 102000001974 Hyaluronidases Human genes 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 229960004788 choline alfoscerate Drugs 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 208000003265 stomatitis Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 108050009363 Hyaluronidases Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000002225 anti-radical effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004195 gingiva Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- QAQJMLQRFWZOBN-UHFFFAOYSA-N 2-(3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl)-2-hydroxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)C1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010037763 Radiation mucositis Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000542 fatty acid esters of ascorbic acid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N n-alpha-eicosene Natural products CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Description
Descrizione del brevetto per invenzione industriale avente per titolo:
?COMPOSIZIONI TOPICHE PER IL MANTENIMENTO E/O RIPRISTINO DELL?INTEGRIT? DELLE MUCOSE E DELL?EPIDERMIDE LESA?
L?invenzione ha per oggetto composizioni topiche per il mantenimento e/o ripristino dell?integrit? delle mucose e dell?epidermide lesa.
STATO DELLA TECNICA
L?integrit? del tessuto cutaneo e mucoso pu? essere alterata da svariate cause, esogene ed endogene, come ad esempio le carenze vitaminiche, la scorretta nutrizione, la carenza igienica, le infezioni batteriche, virali, micotiche, le disbiosi intestinali, le alterazioni della flora microbica mucosale, gli squilibri endocrini, le patologie debilitanti, i fattori ereditari e anche i fattori meccanici, fisici, chimici, traumatici, le radiazioni, etc.
EP2646036 descrive composizioni utili per mantenere e ripristinare l?integrit? di mucose ed epidermide comprendenti colina alfoscerato e acido ialuronico.
La colina alfoscerato ? nota come sostanza nootropa in grado di migliorare il trofismo delle cellule cerebrali (attivandone l?irrorazione sanguigna e il metabolismo cellulare) e quindi le funzioni intellettive. WO93/19730 descrive il suo impiego sulla pelle e sui capelli con azione idratante, emolliente, elasticizzante, restitutiva, volumizzante.
Come descritto in WO93/19730, la colina alfoscerato ? praticamente priva di tossicit? sistemica e ha una marcata tollerabilit? topica. In campo farmaceutico ? noto il suo impiego in composizioni iniettabili e in composizioni orali per il trattamento delle alterazioni delle funzioni cognitive e come possibile fattore di secrezione dell?ormone della crescita.
L?acido ialuronico, largamente presente in diversi tessuti del corpo umano e animale, ha un?elevata viscoelasticit? e la capacit? di trattenere acqua, fino a 1000 volte il suo peso.
E? diffusamente impiegato per lo pi? in forma di ialuronato sodico in formulazioni cosmetiche e farmaceutiche per le sue propriet? mucoadesive, antiinfiammatorie e riparative.
L?ascorbile palmitato (AP), una forma liposolubile della vitamina C, ? utile per proteggere i lipidi dalla perossidazione e viene utilizzato principalmente nei cosmetici in concentrazioni comprese fra lo 1,0 e lo 0,1% p/p con finalit? antiossidante e antiradicalica nei trattamenti anti-invecchiamento. Affine ai lipidi, penetra facilmente pelle e mucose, dove svolge azione antiossidante evitando l'invecchiamento cellulare e la degenerazione del collagene. L'ascorbil palmitato ? anche venduto sotto forma di integratore, per favorire l'assorbimento del ferro, aiutare la circolazione sanguigna e coadiuvare la formazione di collagene, contribuendo ad evitare l'insorgere di dolori articolari e reumatismi. Viene anche utilizzato come additivo alimentare (E304) con finalit? antiossidanti. E? inoltre noto che l?acido ascorbico ed i suoi esteri in particolare, l?L-ascorbil palmitato, sono dotati di significativa attivit? di inibizione delle ialuronidasi, enzimi responsabili della degradazione dell?acido ialuronico.
E? particolarmente sentita l?esigenza di composizioni utili per mantenere e ripristinare l?integrit? delle mucose che siano adattabili a vari tipi di formulazione per diversi siti di applicazione e che presentino effetti sinergici fra i componenti e migliorata stabilit? nei confronti delle ialuronidasi.
Descrizione dell?invenzione
Si ? ora trovato che l?impiego topico su mucose ed epidermide lesa di una associazione di acido ialuronico ad alto peso molecolare, un estere di acido ascorbico, preferibilmente ascorbil-palmitato, in concentrazioni inferiori o uguali allo 0,05% p/p, e colina alfoscerato in matrice bio/mucoadesiva permette di mantenere e ripristinare l?integrit? del tessuto mucoso ed epidermico con una efficacia e una flessibilit? applicativa superiori a quelle delle formulazioni note.
L?associazione dell?invenzione ? particolarmente utile per il trattamento di situazioni irritative-infiammatorie delle mucose e dell?epidermide lesa (ustioni, piaghe, eritemi solari, dermatiti e simili condizioni).
L?invenzione fornisce pertanto composizioni topiche mucoadesive comprendenti acido ialuronico o un suo sale, colina alfoscerato, un estere di acido ascorbico in concentrazione compresa tra 0,050% p/v p/p e 0,0004% p/v p/p ed almeno un eccipiente o veicolo farmaceuticamente accettabile.
L?estere di acido ascorbico, preferibilmente ascorbil palmitato, ? presente nelle formulazioni dell?invenzione in concentrazioni inferiori a quelle impiegate solitamente per uso come agente anti-ossidante e anti-radicalico (0,500-0,100% p/p) in formulazioni convenzionali cosmetiche e dermatologiche.
Il peso molecolare medio dell?acido ialuronico ? preferibilmente compreso tra 800.000 e 4.000.000 Da. L?acido ialuronico pu? essere presente nelle formulazioni in forma di sale sodico in concentrazioni variabili tra 20,000% p/p e 0,0005% p/p.
La colina alfoscerato ? presente in concentrazioni da 0,0005 a 10,000% p/p e preferibilmente da 0,001% a 1,000% p/p.
Le composizioni dell?invenzione contengono inoltre uno o pi? agenti mucoadesivi scelti fra beta-glucano, sodio carbossimetil beta-glucano, chitosano, carbossimetil chitosano, carbossimetilcellulosa, idrossietilcellulosa, carbomer, PVA (polivinil alcol), PVP (polivinilpirrolidone), Polycarbophil (Polyacrylic acid crosslinked with divinyl glycol), PVM/MA Copolimero (copolymer of methyl vinyl ether and maleic anhydride), VP/EICOSENE copolimero (1-Vinyl-2-pyrrolidinone - 1-icosene (1:1)).
Secondo un ulteriore aspetto, le composizioni dell?invenzione possono inoltre comprendere ulteriori principi attivi utili per il trattamento topico delle mucose, come ad esempio quelli descritti in Martindale, The Complete Drug Reference, 34th Edition.
Le composizioni dell?invenzione possono essere formulate in modo adatto alla somministrazione per via topica secondo metodi convenzionali ben noti, descritti ad esempio in Remington, The Science and Practice of Pharmacy, 20th Edition.
Possono essere aggiunti anche eccipienti o veicoli noti, ad esempio agenti filmanti, per ottimizzare l?uso specifico delle composizioni, come ad esempio quelli descritti in Handbook of Pharmaceutical Excipients, 6th Edition, Pharmaceutical Press.
Esempi di formulazioni preferite sono gel, emulsioni (olio in acqua (o/w) e acqua in olio (w/o)), creme, pomate, spray, polveri, lozioni, schiume.
Composizioni particolarmente preferite sono in forma di gel acquoso (idrogel) che pu? essere ottenuto utilizzando un polimero farmaceuticamente accettabile in grado di assorbire una notevole quantit? di acqua e di aderire cos? alla mucosa (mucoadesivit?).
La mucoadesivit? delle composizioni dell?invenzione assicura una adeguata permanenza sulle mucose soggette all?azione dilavante di fattori fisici e meccanici che possono diminuire il tempo di permanenza del principio attivo, ad esempio nel caso della mucosa orale.
Le composizioni dell?invenzione, adatte all?uso umano o veterinario, associano all?azione antinfiammatoria e riparatrice tissutale dell?acido ialuronico l?azione filmante e protettiva delle matrici formulative bio/mucoadesive contenenti colina alfoscerato e l?azione antiialuronidasica dell?ascorbil palmitato a basse concentrazioni.
L?attivit? antiialuronidasica dell?ascorbil palmitato sinergizza con l?azione dell?acido ialuronico, sia endogeno tissutale che apportato per via esogena. L?azione antiialuronidasica ? di fondamentale importanza per aumentare l?efficacia antinfiammatoria e riparatrice tissutale dell?acido ialuronico proteggendolo dell?azione enzimatica delle ialuronidasi endogene e batteriche garantendone la permanenza funzionale e prolungata in situ e quindi una maggiore efficacia legata ad una maggiore biodisponibilit? e integrit? strutturale.
Inoltre l?azione antiialuronidasica esplica anche azione antibatterica/antinfiammatoria; infatti, molto batteri esplicano un?azione infiammatoria tramite la produzione di specifiche ialuronidasi che favoriscono la colonizzazione nei tessuti, favorendo quindi l?instaurarsi e il diffondersi delle infezioni/contaminazioni batteriche a livello locale.
Sulla base di quanto sopra esposto, l?azione antinfiammatoria/riparatrice tissutale dell?HA viene protetta e fortemente potenziata dall?azione antiialuronidasica e dalla presenza della matrice filmante e bio/mucoadesiva in grado di realizzare un ambiente favorevole alla protezione e riparazione tissutale (wound healing).
Le composizioni dell?invenzione possono essere applicate sulle mucose esterne, come ad esempio la mucosa della bocca e del cavo orale in generale, la mucosa nasale, la mucosa oculare, la mucosa auricolare, le mucose dei genitali, la mucosa anale e rettale.
Le composizioni dell?invenzione sono utili nella prevenzione e nel trattamento di affezioni infiammatorie e/o lesive della mucosa orale, nella prevenzione e/o nel trattamento delle gengive lese e/o infiammate e nel trattamento delle mucositi da radiazioni.
Per infiammazione e lesione della mucosa orale si intendono ad esempio gengiviti, mucositi (afte comprese afte ricorrenti), stomatiti, glossiti, etc. Queste affezioni possono avere eziologia diversa, ad esempio possono avere cause meccaniche, chimiche, patologiche (infezioni, disbiosi del cavo orale o intestinali).
Gli esempi di seguito riportati illustrano ulteriormente l?invenzione. Le percentuali si intendono in parti in peso (p/p) sul volume totale della composizione.
Esempio 1 - Composizione liquida per la mucosa orale
Esempio 2 - Composizione gel per il trattamento delle afte orali
Esempio 3 - Composizione gel per il trattamento delle mucositi orali
Esempio 4 - Composizione liquida per il trattamento delle mucositi orali
Esempio 5 - Composizione gel per l?impiego sulla mucosa nasale
Esempio 6 - Composizione liquida per l?impiego sulla mucosa oculare
Esempio 7 - Composizione liquida per l?impiego sulla mucosa auricolare
Esempio 8 - Composizione liquida per l?impiego sulla mucosa vaginale e vulvare
Esempio 9 - Composizione gel per l?impiego sulla mucosa vaginale e vulvare
Esempio 10 - Composizione in gel per l?impiego sulla mucosa dei genitali maschili
Esempio 11 - Composizione in gel per l?impiego ano-rettale
Esempio 12 - Composizione in gel per il trattamento della gengiva infiammata
Esempio 13 - Composizione in gel per il trattamento della gengiva lesa
Esempio 14 - ovulo vaginale
Esempio 15 - Composizione anorettale in clisma
Claims (9)
- RIVENDICAZIONI 1. Composizioni topiche mucoadesive comprendenti acido ialuronico o un suo sale, colina alfoscerato, un estere di acido ascorbico in concentrazione compresa tra 0,050% p/p e 0,0004% p/p ed almeno un eccipiente o veicolo farmaceuticamente accettabile.
- 2. Composizioni secondo la rivendicazione 1 in cui l?estere di acido ascorbico ? l?ascorbil palmitato.
- 3. Composizioni secondo la rivendicazione 1 o 2 in cui l?acido ialuronico o un suo sale farmaceuticamente accettabile ha un peso molecolare compreso tra 800.000 e 4.000.000 Da.
- 4. Composizioni secondo la rivendicazione 3, in cui l?acido ialuronico ? in forma di sale sodico ad una concentrazione compresa tra 20,000% p/p e 0,0005% p/p.
- 5. Composizioni secondo una delle rivendicazioni da 1 a 4 in cui la concentrazione di colina alfoscerato ? compresa tra 0,0005% p/p e 10,000% p/p.
- 6. Composizioni secondo una delle rivendicazioni da 1 a 5 in cui l?eccipiente o veicolo farmaceuticamente accettabile ? scelto fra beta-glucano, sodio carbossimetil beta-glucano, chitosano, carbossimetil chitosano, carbossimetilcellulosa, idrossietilcellulosa, carbomer, polivinil alcol, polivinilpirrolidone, Polycarbophil, PVM/MA Copolimero (copolymer of methyl vinyl ether and maleic anhydride), VP/EICOSENE copolimero (1-Vinyl-2-pyrrolidinone - 1-icosene (1:1)).
- 7. Composizioni secondo una delle rivendicazioni da 1 a 6 in forma di idrogel, lipogel, gel anidri, emulsioni O/W e W/O, soluzioni, sospensioni.
- 8. Composizioni delle rivendicazioni 1-6 per uso topico per il mantenimento e ripristino dell?integrit? di mucose e della cute e per la prevenzione e trattamento di affezioni infiammatorie a carico delle stesse.
- 9. Composizioni per l?uso della rivendicazione 8 in cui le mucose comprendono le mucose orali, gengivali, nasali, oculari, auricolari, vaginali, vulvari, ano-rettali, genitali.
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102020000004069A IT202000004069A1 (it) | 2020-02-27 | 2020-02-27 | Composizioni topiche per il mantenimento e/o ripristino dell’integrità delle mucose e dell’epidermide lesa |
IL295822A IL295822A (en) | 2020-02-27 | 2021-02-25 | Local preparations designed to maintain and/or restore the integrity of the damaged mucosa and epidermis |
MX2022010645A MX2022010645A (es) | 2020-02-27 | 2021-02-25 | Composiciones topicas dise?adas para mantener y/o restaurar la integridad de la mucosa y epidermis da?ada. |
KR1020227033288A KR20220146582A (ko) | 2020-02-27 | 2021-02-25 | 점막 및 손상된 표피의 완전성을 유지 및/또는 회복시키기 위해 고안된 국소용 조성물 |
EP21714664.6A EP4110288B1 (en) | 2020-02-27 | 2021-02-25 | Topical compositions designed to maintain and/or restore the integrity of the mucosa and damaged epidermis |
CA3169514A CA3169514A1 (en) | 2020-02-27 | 2021-02-25 | Topical compositions designed to maintain and/or restore the integrity of the mucosa and damaged epidermis |
PCT/IB2021/051573 WO2021171215A1 (en) | 2020-02-27 | 2021-02-25 | Topical compositions designed to maintain and/or restore the integrity of the mucosa and damaged epidermis |
JP2022550124A JP2023522295A (ja) | 2020-02-27 | 2021-02-25 | 粘膜及び損傷した表皮の完全性を維持及び/又は回復するように設計された局所組成物 |
BR112022016597A BR112022016597A2 (pt) | 2020-02-27 | 2021-02-25 | Processo para sulfatação direta de polissacarídeos em um solvente ecologicamente aceitável |
CN202180017478.3A CN115209873A (zh) | 2020-02-27 | 2021-02-25 | 被设计成维持和/或恢复粘膜和受损表皮完整性的局部组合物 |
US17/904,957 US20230114487A1 (en) | 2020-02-27 | 2021-02-25 | Topical compositions designated to maintain and/or restore the integrity of the mucosa and damaged epidermis |
PE2022001497A PE20221833A1 (es) | 2020-02-27 | 2021-02-25 | Composiciones topicas disenadas para mantener y/o restaurar la integridad de la mucosa y epidermis danada |
AU2021225476A AU2021225476A1 (en) | 2020-02-27 | 2021-02-25 | Topical compositions designed to maintain and/or restore the integrity of the mucosa and damaged epidermis |
CONC2022/0010763A CO2022010763A2 (es) | 2020-02-27 | 2022-07-29 | Composiciones tópicas diseñadas para mantener y/o restaurar la integridad de la mucosa y epidermis dañada |
CL2022002324A CL2022002324A1 (es) | 2020-02-27 | 2022-08-25 | Composiciones tópicas diseñadas para mantener y/o restaurar la integridad de mucosa y epidermis dañada |
US18/477,609 US20240024352A1 (en) | 2020-02-27 | 2023-09-29 | Topical compositions designated to maintain and/or restore the integrity of the mucosa and damaged epidermis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102020000004069A IT202000004069A1 (it) | 2020-02-27 | 2020-02-27 | Composizioni topiche per il mantenimento e/o ripristino dell’integrità delle mucose e dell’epidermide lesa |
Publications (1)
Publication Number | Publication Date |
---|---|
IT202000004069A1 true IT202000004069A1 (it) | 2021-08-27 |
Family
ID=70738958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT102020000004069A IT202000004069A1 (it) | 2020-02-27 | 2020-02-27 | Composizioni topiche per il mantenimento e/o ripristino dell’integrità delle mucose e dell’epidermide lesa |
Country Status (15)
Country | Link |
---|---|
US (2) | US20230114487A1 (it) |
EP (1) | EP4110288B1 (it) |
JP (1) | JP2023522295A (it) |
KR (1) | KR20220146582A (it) |
CN (1) | CN115209873A (it) |
AU (1) | AU2021225476A1 (it) |
BR (1) | BR112022016597A2 (it) |
CA (1) | CA3169514A1 (it) |
CL (1) | CL2022002324A1 (it) |
CO (1) | CO2022010763A2 (it) |
IL (1) | IL295822A (it) |
IT (1) | IT202000004069A1 (it) |
MX (1) | MX2022010645A (it) |
PE (1) | PE20221833A1 (it) |
WO (1) | WO2021171215A1 (it) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019730A1 (en) | 1992-03-30 | 1993-10-14 | Flarer S.A. Pharmaceutical Fine Chemicals | Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use |
US20080015155A1 (en) * | 2002-04-09 | 2008-01-17 | Sinclair Pharmaceuticals Ltd. | Compositions and Methods for the Treatment of Inflammatory Conditions of the Mucosae, Skin and the Eye |
WO2012073191A1 (en) * | 2010-11-30 | 2012-06-07 | Ricerfarma S.R.L. | Topical compositions for preserving or restoring the integrity of mucosae |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004002001A1 (de) * | 2004-01-14 | 2005-08-11 | Reinmüller, Johannes, Dr.med. | Mittel zur Behandlung von entzündlichen Erkrankungen |
US20070196311A1 (en) * | 2006-02-21 | 2007-08-23 | Gross Dennis F | Methods and kits for topical administration of hyaluronic acid |
FR2946252B1 (fr) * | 2009-06-08 | 2011-07-29 | Fabre Pierre Dermo Cosmetique | Bis esters d'acide gras insature sur l'acide ascorbique et leurs utilisations cosmetiques |
-
2020
- 2020-02-27 IT IT102020000004069A patent/IT202000004069A1/it unknown
-
2021
- 2021-02-25 CN CN202180017478.3A patent/CN115209873A/zh active Pending
- 2021-02-25 US US17/904,957 patent/US20230114487A1/en not_active Abandoned
- 2021-02-25 AU AU2021225476A patent/AU2021225476A1/en active Pending
- 2021-02-25 JP JP2022550124A patent/JP2023522295A/ja active Pending
- 2021-02-25 CA CA3169514A patent/CA3169514A1/en active Pending
- 2021-02-25 KR KR1020227033288A patent/KR20220146582A/ko unknown
- 2021-02-25 EP EP21714664.6A patent/EP4110288B1/en active Active
- 2021-02-25 WO PCT/IB2021/051573 patent/WO2021171215A1/en active Application Filing
- 2021-02-25 MX MX2022010645A patent/MX2022010645A/es unknown
- 2021-02-25 PE PE2022001497A patent/PE20221833A1/es unknown
- 2021-02-25 BR BR112022016597A patent/BR112022016597A2/pt unknown
- 2021-02-25 IL IL295822A patent/IL295822A/en unknown
-
2022
- 2022-07-29 CO CONC2022/0010763A patent/CO2022010763A2/es unknown
- 2022-08-25 CL CL2022002324A patent/CL2022002324A1/es unknown
-
2023
- 2023-09-29 US US18/477,609 patent/US20240024352A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019730A1 (en) | 1992-03-30 | 1993-10-14 | Flarer S.A. Pharmaceutical Fine Chemicals | Cosmetical or pharmaceutical compositions comprising deacylated glycerophospholipids for topical use |
US20080015155A1 (en) * | 2002-04-09 | 2008-01-17 | Sinclair Pharmaceuticals Ltd. | Compositions and Methods for the Treatment of Inflammatory Conditions of the Mucosae, Skin and the Eye |
WO2012073191A1 (en) * | 2010-11-30 | 2012-06-07 | Ricerfarma S.R.L. | Topical compositions for preserving or restoring the integrity of mucosae |
EP2646036A1 (en) | 2010-11-30 | 2013-10-09 | RICERFARMA Srl | Topical compositions for preserving or restoring the integrity of mucosae |
Non-Patent Citations (1)
Title |
---|
"Remington, the Science and practice of Pharmacy", PHARMACEUTICAL PRESS |
Also Published As
Publication number | Publication date |
---|---|
CN115209873A (zh) | 2022-10-18 |
PE20221833A1 (es) | 2022-11-29 |
US20230114487A1 (en) | 2023-04-13 |
EP4110288A1 (en) | 2023-01-04 |
BR112022016597A2 (pt) | 2023-04-04 |
WO2021171215A1 (en) | 2021-09-02 |
AU2021225476A1 (en) | 2022-10-13 |
EP4110288B1 (en) | 2024-03-27 |
US20240024352A1 (en) | 2024-01-25 |
MX2022010645A (es) | 2022-09-23 |
CA3169514A1 (en) | 2021-09-02 |
CL2022002324A1 (es) | 2023-03-31 |
CO2022010763A2 (es) | 2022-08-19 |
JP2023522295A (ja) | 2023-05-30 |
KR20220146582A (ko) | 2022-11-01 |
IL295822A (en) | 2022-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2248042T5 (es) | Composición tópica que comprende n-acetilglucosamina. | |
US9050351B2 (en) | Topical compositions designed to maintain or restore the integrity of the mucous membranes | |
US5643584A (en) | Aqueous gel retinoid dosage form | |
ES2318061T3 (es) | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. | |
EP2520279A1 (en) | Thermoreversible gel pharamaceutical compositions for odontoiatric use | |
JP2003524635A (ja) | 活性作用物の局所デリバリー用キトサンバイオポリマー | |
WO2005074883A1 (en) | Aqueous compositions containing mixtures of synthetic polymers and biopolymers, useful in the treatment of skin and mucosal tissues dryness, and suitable as vehicles of active ingredients | |
US20140199413A1 (en) | Melatonin and an antimicrobial or antibacterial agent for the treatment of acne | |
RU2420257C1 (ru) | Стоматологический гель с хлоргексидином и дибунолом для лечения воспалительных заболеваний пародонта и слизистой оболочки полости рта | |
ES2710704T3 (es) | Composición filmógena y su uso para el tratamiento de afecciones cutáneas | |
IT202000004069A1 (it) | Composizioni topiche per il mantenimento e/o ripristino dell’integrità delle mucose e dell’epidermide lesa | |
KR20150090920A (ko) | 염증성 피부 질환을 예방하고 치료하기 위한 방법 | |
IT202000022042A1 (it) | Composizioni topiche antivirali comprendenti acido ialuronico e carragenina | |
KR20010069757A (ko) | 폴리크레줄렌을 이용한 신규 구강 청결 소독제에 제조에관한 의약 조성물 | |
ITMI20110954A1 (it) | Combinazioni per il trattamento delle mucositi vaginali o rettali | |
ITMI970468A1 (it) | Formulazioni per uso topico contenenti carragenina e un sale dell'acido ialuronico |